Six years af­ter with­draw­ing IPO, Abpro takes SPAC route to Nas­daq — with plans to take HER2 bis­pe­cif­ic to clin­ic

Abpro, an an­ti­body mak­er work­ing on T cell en­gagers that tar­get HER2+ can­cer types, is go­ing pub­lic through merg­ing with a SPAC com­pa­ny dubbed At­lantic Coastal Ac­qui­si­tion Corp.

The deal — which val­ues Woburn, MA-based Abpro at $725 mil­lion — comes more than six years af­ter the biotech first filed for an IPO. It even­tu­al­ly with­drew the list­ing plans and in­stead earned some cash from a li­cens­ing deal with Chi­na’s Nan­jing Chia Tai-Tian­qing Phar­ma­ceu­ti­cal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER